Alasdair Coles

21.2k total citations · 4 hit papers
199 papers, 13.4k citations indexed

About

Alasdair Coles is a scholar working on Pathology and Forensic Medicine, Immunology and Neurology. According to data from OpenAlex, Alasdair Coles has authored 199 papers receiving a total of 13.4k indexed citations (citations by other indexed papers that have themselves been cited), including 114 papers in Pathology and Forensic Medicine, 53 papers in Immunology and 48 papers in Neurology. Recurrent topics in Alasdair Coles's work include Multiple Sclerosis Research Studies (108 papers), Peripheral Neuropathies and Disorders (37 papers) and Immunotherapy and Immune Responses (36 papers). Alasdair Coles is often cited by papers focused on Multiple Sclerosis Research Studies (108 papers), Peripheral Neuropathies and Disorders (37 papers) and Immunotherapy and Immune Responses (36 papers). Alasdair Coles collaborates with scholars based in United Kingdom, United States and Germany. Alasdair Coles's co-authors include Alastair Compston, Joanne Jones, D. A. S. Compston, David Margolin, Herman Waldmann, G Hale, Edward Fox, Krzysztof Selmaj, Amanda Cox and Eva Havrdová and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Clinical Investigation.

In The Last Decade

Alasdair Coles

187 papers receiving 13.1k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Multiple sclerosis

2008 3.5k citations Alasdair Coles et al. profile →
Multiple sclerosis

2002 1.5k citations Alasdair Coles et al. profile →
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

2012 884 citations Alasdair Coles, Cary Twyman et al. profile →
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

2012 883 citations Jeffrey Cohen, Alasdair Coles et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alasdair Coles United Kingdom	43	9.1k	3.8k	3.3k	2.7k	2.3k	199	13.4k
Robert J. Fox United States	54	7.9k 0.9×	2.6k 0.7×	2.8k 0.9×	2.2k 0.8×	1.8k 0.8×	310	12.8k
Stephen L. Hauser United States	70	8.4k 0.9×	5.9k 1.5×	2.8k 0.9×	2.4k 0.9×	2.3k 1.0×	275	16.9k
Bruce Cree United States	61	8.3k 0.9×	2.7k 0.7×	3.5k 1.1×	1.8k 0.6×	2.1k 0.9×	279	13.0k
Olaf Stüve United States	57	6.4k 0.7×	3.3k 0.9×	2.6k 0.8×	2.4k 0.9×	1.7k 0.7×	251	11.5k
Tanuja Chitnis United States	64	11.2k 1.2×	3.8k 1.0×	5.7k 1.7×	2.3k 0.8×	2.9k 1.3×	365	17.6k
Christian Confavreux France	58	12.8k 1.4×	3.2k 0.8×	5.0k 1.5×	3.2k 1.2×	3.8k 1.6×	175	16.3k
Peter Rieckmann Germany	64	6.8k 0.8×	3.1k 0.8×	2.9k 0.9×	2.4k 0.9×	1.8k 0.8×	266	13.1k
Gilles Edan France	37	13.6k 1.5×	2.3k 0.6×	5.5k 1.7×	2.8k 1.0×	3.9k 1.7×	145	16.2k
D. A. S. Compston United Kingdom	63	7.7k 0.8×	3.5k 0.9×	4.3k 1.3×	2.0k 0.7×	2.5k 1.1×	180	13.5k
Krzysztof Selmaj Poland	61	9.5k 1.1×	5.4k 1.4×	3.6k 1.1×	3.3k 1.2×	2.6k 1.1×	338	17.7k

Countries citing papers authored by Alasdair Coles

Since Specialization

Citations

This map shows the geographic impact of Alasdair Coles's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alasdair Coles with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alasdair Coles more than expected).

Fields of papers citing papers by Alasdair Coles

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alasdair Coles. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alasdair Coles. The network helps show where Alasdair Coles may publish in the future.

Co-authorship network of co-authors of Alasdair Coles

This figure shows the co-authorship network connecting the top 25 collaborators of Alasdair Coles. A scholar is included among the top collaborators of Alasdair Coles based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alasdair Coles. Alasdair Coles is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wamelen, Daniel J. van, Silvia Rota, Monika Hartmann, et al.. (2024). Addressing ethnic disparities in neurological research in the United Kingdom: An example from the prospective multicentre COVID-19 Clinical Neuroscience Study. Clinical Medicine. 24(3). 100209–100209.

Lennox, Belinda, Patrick Waters, Alasdair Coles, et al.. (2022). The serum metabolomic profile of a distinct, inflammatory subtype of acute psychosis. Molecular Psychiatry. 27(11). 4722–4730. 4 indexed citations

Brown, J William L, Ferrán Prados, Daniel R. Altmann, et al.. (2022). Remyelination varies between and within lesions in multiple sclerosis following bexarotene. Annals of Clinical and Translational Neurology. 9(10). 1626–1642. 14 indexed citations

Garjani, Afagh, Rod Middleton, Rachael Hunter, et al.. (2021). COVID-19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapies. Multiple Sclerosis and Related Disorders. 52. 102939–102939. 36 indexed citations

Brown, J William L, Ferrán Prados, Arman Eshaghi, et al.. (2019). Periventricular magnetisation transfer ratio abnormalities in multiple sclerosis improve after alemtuzumab. Multiple Sclerosis Journal. 26(9). 1093–1101. 9 indexed citations

Fox, Edward, David Brassat, Raed Alroughani, et al.. (2017). Alemtuzumab Provides Durable Efficacy Over 6 Years in Patients With Active Relapsing-Remitting Multiple Sclerosis and an Inadequate Response to Prior Therapy in the Absence of Continuous Treatment (CARE-MS II) (S24.006). Neurology. 88(16_supplement). 2 indexed citations

Coles, Alasdair, Alexey Boyко, J. A. Cohen, et al.. (2016). Alemtuzumab provides durable improvements in clinical outcomes in treatment-naive patients with active relapsing-remitting multiple sclerosis over 6 years in the absence of continuous treatment (CARE-MS I).. Multiple Sclerosis Journal. 22. 75–76. 7 indexed citations

Schippling, Sven, Jeffrey A. Cohen, Alasdair Coles, et al.. (2016). Alemtuzumab-Treated Patients with RRMS Demonstrate Durable Slowing of Brain Volume Loss Over 5 Years Despite Most Being Treatment-Free for 4 Years: CARE-MS I and II Extension Study (S51.001). Neurology. 86(16_supplement). 2 indexed citations

Barkhof, Frederik, Jeffrey A. Cohen, Alasdair Coles, et al.. (2016). RRMS Patients Switching from SC IFNB-1a to Alemtuzumab in the CARE-MS I and II Extension Study Have a Reduced Rate of Brain Volume Loss (P6.183). Neurology. 86(16_supplement). 2 indexed citations

10.

Coles, Alasdair, Douglas L. Arnold, Jeffrey A. Cohen, et al.. (2015). Alemtuzumab Slows Brain Volume Loss Over 4 Years Despite Most Relapsing-Remitting Multiple Sclerosis Patients Not Receiving Treatment for 3 Years (P7.263). Neurology. 84(14_supplement). 4 indexed citations

11.

Havrdová, Eva, Gavin Giovannoni, Douglas L. Arnold, et al.. (2015). Durable Effect of Alemtuzumab on Clinical Outcomes in Patients With Relapsing-Remitting Multiple Sclerosis Who Relapsed on Prior Therapy: 4-Year Follow-up of CARE-MS II (P7.276). Neurology. 84(14_supplement). 3 indexed citations

12.

Singer, B., Edward Fox, Stephen Krieger, et al.. (2015). Durable Efficacy of Alemtuzumab in Patients With Highly Active Relapsing-Remitting Multiple Sclerosis Who Relapsed on a Prior Therapy (P7.269). Neurology. 84(14_supplement). 1 indexed citations

13.

Wray, Sibyl, Alexey Boyко, Tiffany J. Braley, et al.. (2015). Administration of Alemtuzumab on Nonconsecutive Days Does Not Impact Infusion-Associated Reactions, Efficacy, or Lymphocyte Depletion (P7.277). Neurology. 84(14_supplement). 2 indexed citations

14.

Tuohy, Orla, et al.. (2013). Immune competence after alemtuzumab treatment of multiple sclerosis. Neurology. 81(10). 872–876. 102 indexed citations

15.

Hartung, Hans, Timothy Vollmer, Douglas L. Arnold, et al.. (2013). Alemtuzumab Reduces MS Disease Activity in Active Relapsing-Remitting Multiple Sclerosis Patients Who Had Disease Activity on Prior Therapy (P07.093). Neurology. 80(7_supplement). 2 indexed citations

16.

Sørensen, Per Soelberg, Douglas L. Arnold, Jeffrey A. Cohen, et al.. (2013). Immunogenicity of Alemtuzumab Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients in the CARE-MS II Study (P07.101). Neurology. 80(7_supplement). 4 indexed citations

17.

Giovannoni, Gavin, Douglas L. Arnold, Jeffrey Cohen, et al.. (2013). Disability Improvement with Alemtuzumab vs. Interferon beta-1a in Relapsing-Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE-MS II) (P07.120). Neurology. 80(7_supplement). 1 indexed citations

18.

Wray, Sibyl, Douglas L. Arnold, Jeffrey Cohen, et al.. (2013). Comparison of Infection Risk with Alemtuzumab and SC IFNB-1a in Patients with Multiple Sclerosis Who Experienced Disease Activity While on Prior Therapy (CARE-MS II) (P01.172). Neurology. 80(7_supplement). 1 indexed citations

19.

LaGanke, Christopher, Douglas L. Arnold, Jeffrey Cohen, et al.. (2013). Adverse Event Profile of Alemtuzumab over Time in Active Relapsing-Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE-MS II) (P01.174). Neurology. 80(7_supplement). 3 indexed citations

20.

Coles, Alasdair. (2000). Thomas Willis concept of the neural reflex A reappraisal. Journal of Neurology Neurosurgery & Psychiatry. 69(3). 417. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact